<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02625441</url>
  </required_header>
  <id_info>
    <org_study_id>FBCG-01-2015</org_study_id>
    <secondary_id>2015-002323-25</secondary_id>
    <nct_id>NCT02625441</nct_id>
  </id_info>
  <brief_title>Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer</brief_title>
  <acronym>BOLD-1</acronym>
  <official_title>A Randomized Phase III Study Comparing Trastuzumab, Pertuzumab Plus Docetaxel (TPD) Followed by 3 Cycles of Chemotherapy to the Current Standard Regimen as the Treatments of Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized clinical trial compares two systemic treatments for HER2-positive breast&#xD;
      cancer. The treatments are given either prior to breast surgery (as neoadjuvant treatment) or&#xD;
      after breast surgery (as adjuvant treatment). In the investigational group (Group A) the&#xD;
      study participants will receive a combination of two drugs directed at HER2 (two anti-HER2&#xD;
      antibodies) plus a chemotherapy agent (docetaxel) for a brief duration, and the patients&#xD;
      allocated to the comparator group (Group B) will be treated with chemotherapy plus one&#xD;
      anti-HER2 treatment (trastuzumab) for one year.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, patients who have been diagnosed with HER2-positive early breast cancer will&#xD;
      be randomly allocated in a 1:1 ratio to receive either three 3-weekly cycles of trastuzumab,&#xD;
      pertuzumab and docetaxel (TPD) for a total duration of 9 weeks, followed by three further&#xD;
      cycles of chemotherapy (Group A) or three 3-weekly cycles of trastuzumab and docetaxel (TD)&#xD;
      followed by three further cycles of chemotherapy and single-agent anti-HER2 antibody&#xD;
      treatment to complete one year of anti-HER2 treatment (Group B). These systemic treatments&#xD;
      may be administered either prior to breast surgery (as neoadjuvant treatment) or after breast&#xD;
      surgery (as adjuvant treatment). The study participants are required to have histologically&#xD;
      verified breast cancer with a moderate to high risk for breast cancer recurrence despite&#xD;
      macroscopically complete surgery for the breast tumor. The moderate/high risk of breast&#xD;
      cancer recurrence is defined by presence of cancer in the axillary lymph nodes, or if the&#xD;
      axillary lymph nodes do not contain cancer, by presence of a tumor larger than one centimeter&#xD;
      in the breast. The study patients are followed up during the study treatments and after their&#xD;
      completion with physical examination, blood tests, cardiac tests and, whenever indicated,&#xD;
      with imaging. Approximately 700 patients will be randomly allocated to each of the two&#xD;
      groups. The study hypothesis is that the regimen containing TPD may be more effective than&#xD;
      the Group B treatment despite its brief duration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Invasive disease-free survival</measure>
    <time_frame>7 years</time_frame>
    <description>Time from the date of randomization to cancer recurrence or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>7 years</time_frame>
    <description>Time from the date of randomization to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant disease-free survival</measure>
    <time_frame>7 years</time_frame>
    <description>Time from the date of randomization to distant recurrence of cancer or to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricle ejection fractions</measure>
    <time_frame>3 years</time_frame>
    <description>Cardiac ejection fraction measured with echocardiography or isotope cardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events of the treatments</measure>
    <time_frame>7 years</time_frame>
    <description>Adverse events considered to be related to the treatments.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1366</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Short anti-HER2 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pertuzumab 840 mg, i.v., then 420 mg i.v., 3-weekly for 3 cycles; Trastuzumab 8 mg/kg, i.v., then 6 mg/kg, 3-weekly for 3 cycles; Docetaxel 75 mg/m2, i.v., 3-weekly for 3 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard anti-HER2 treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trastuzumab 8 mg/kg, i.v., then 6 mg/kg, 3-weekly for 3 cycles; Docetaxel 75 mg/m2, i.v., 3-weekly for 3 cycles; Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>Pertuzumab 420 mg i.v. 3-weekly for 3 cycles</description>
    <arm_group_label>Short anti-HER2 treatment</arm_group_label>
    <other_name>Perjeta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year</description>
    <arm_group_label>Standard anti-HER2 treatment</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has provided a written informed consent prior to study-specific screening&#xD;
             procedures, with the understanding that she has the right to withdraw from the study&#xD;
             at any time, without prejudice.&#xD;
&#xD;
          -  Woman &gt; 18 years of age.&#xD;
&#xD;
          -  Histologically confirmed invasive breast cancer.&#xD;
&#xD;
          -  HER2-positive breast cancer (preferably assessed with in situ hybridization; CISH,&#xD;
             FISH or SISH; if not available with immunohistochemistry 3+)&#xD;
&#xD;
          -  A high risk of breast cancer recurrence with one of the following: i) Pathological N0&#xD;
             with the longest invasive tumor diameter &gt;10 mm; ii) Histologically confirmed regional&#xD;
             node positive disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of distant metastases.&#xD;
&#xD;
          -  Inflammatory breast cancer.&#xD;
&#xD;
          -  Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure,&#xD;
             symptomatic coronary artery disease and cardiac arrhythmia not well controlled with&#xD;
             medication) or myocardial infarction within the last 12 months.&#xD;
&#xD;
          -  Left ventricular ejection fraction less than 50% (or under the institutional normal&#xD;
             reference range) assessed by echocardiography or isotope cardiography.&#xD;
&#xD;
          -  ER and HER-2 status (via in situ hybridization or immunohistochemistry) not&#xD;
             determined.&#xD;
&#xD;
          -  The WHO performance status &gt; 1.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Women of childbearing potential unless using a reliable and appropriate contraceptive&#xD;
             method. Women must have been amenorrheic for at least 12 months prior to study entry&#xD;
             to be considered postmenopausal and to have no childbearing potential. Women of&#xD;
             childbearing potential (menstruating within 12 months of study entry), or with no&#xD;
             hysterectomy and age &lt; 55, must have a negative pregnancy test at baseline.&#xD;
&#xD;
          -  Randomization more than 12 weeks after the date of breast surgery.&#xD;
&#xD;
          -  Organ allografts with immunosuppressive therapy required.&#xD;
&#xD;
          -  Major surgery (except breast surgery) within 4 weeks prior to study treatment start,&#xD;
             or lack of complete recovery from the effects of major surgery.&#xD;
&#xD;
          -  Participation in any investigational drug study within 4 weeks preceding treatment&#xD;
             start.&#xD;
&#xD;
          -  Patients with a history of uncontrolled seizures, central nervous system disorders or&#xD;
             psychiatric disability judged by the investigator to be clinically significant&#xD;
             precluding study participation.&#xD;
&#xD;
          -  Multifocal breast cancer when the largest cancer focus is not HER2-positive.&#xD;
&#xD;
          -  History of another malignancy or contralateral invasive breast cancer within the last&#xD;
             five years except cured basal cell carcinoma of skin or carcinoma in situ of the&#xD;
             uterine cervix (exception: patients with bilateral HER2-positive breast cancer are&#xD;
             eligible).&#xD;
&#xD;
          -  One or more of the following: Blood hemoglobin &lt; 10.0 g/dL, neutrophils &lt; 1.5 x 109/L;&#xD;
             platelet count &lt; 120 x 109/L; Serum/plasma creatinine &gt; 1.5 x Upper Limit of Normal&#xD;
             (ULN); Serum/plasma bilirubin &gt; ULN; Serum/plasma ALT and/or AST &gt; 1.5 x ULN;&#xD;
             Serum/plasma alkaline phosphatase &gt; 2.5 x ULN&#xD;
&#xD;
          -  Serious uncontrolled infection or other serious uncontrolled concomitant disease.&#xD;
&#xD;
          -  Unwilling or unable to comply with the protocol for the duration of the study.&#xD;
&#xD;
          -  History of hypersensitivity to the investigational products or to drugs with similar&#xD;
             chemical structures.&#xD;
&#xD;
          -  Pre-existing motor or sensory neurotoxicity of a severity ≥ grade 2 by CTCAE version&#xD;
             4, unless related to mechanical etiology.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heikki Joensuu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heikki Joensuu, M.D.</last_name>
    <phone>094711</phone>
    <phone_ext>+358</phone_ext>
    <email>heikki.joensuu@hus.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heikki Joensuu, MD</last_name>
      <phone>47173200</phone>
      <phone_ext>09</phone_ext>
      <email>heikki.joensuu@hus.fi</email>
    </contact>
    <contact_backup>
      <last_name>Raija 09 Husa</last_name>
      <phone>4711</phone>
      <phone_ext>09</phone_ext>
      <email>raija.husa@hus.fi</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 5, 2015</study_first_submitted>
  <study_first_submitted_qc>December 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2015</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Heikki Joensuu</investigator_full_name>
    <investigator_title>Professor, Research Director</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>docetaxel</keyword>
  <keyword>pertuzumab</keyword>
  <keyword>trastuzumab</keyword>
  <keyword>HER2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

